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Abstract
Background: Hepatitis C virus (HCV) is a major causative agent of liver associated diseases leading to the
development of hepatocellular carcinoma (HCC) all over the world and genotype-3a responsible for most of the
cases in Pakistan. Due to the limited efficiency of current chemotherapy of interferon-a (IFN-a) and ribavirin
against HCV infection alternative options are desperately needed out of which the recently discovered RNAi
represent a powerful silencing approach for molecular therapeutics through a sequence-specific RNA degradation
process to silence virus infection or replication. HCV translation is mediated by a highly conserved internal
ribosome entry site (IRES) within the 5’UTR region making it a relevant target for new drug development.
Materials and methods: The present study was proposed to assess and explore the possibility of HCV silencing
using siRNA targeting 5’UTR. For this analysis full length HCV 5’UTR of HCV-3a (pCR3.1/5’UTR) was tagged with GFP
protein for in vitro analysis in Huh-7 cells. siRNA targeting 5’UTR were designed, and tested against constructed
vector in Huh-7 cell line both at RNA and Protein levels. Furthermore, the effect of these siRNAs was confirmed in
HCV-3a serum infected Huh-7 cell line.
Results: The expression of 5’UTR-GFP was dramatically reduced both at mRNA and protein levels as compared
with Mock transfected and control siRNAs treated cells using siRNAs against IRES of HCV-3a genotype. The
potential of siRNAs specificity to inhibit HCV-3a replication in serum-infected Huh-7 cells was also investigated;
upon treatment with siRNAs a significant decrease in HCV viral copy number and protein expression was observed.
Conclusions: Overall, the present work of siRNAs against HCV 5’UTR inhibits HCV-3a expression and represents
effective future therapeutic opportunities against HCV-3a genotype.
Background
A large number of people die each year from liver fail-
ure and cancer caused by HCV infection as more than
3% world population is chronically infected with this
viral pathogen especially in developing countries includ-
ing Pakistan where 6% of population is infected [1,2]. In
40-60% of HCV infected individuals persistent infection
is mainly associated with liver cirrhosis and steatosis
leading to HCC [3,4]. The standard treatment for HCV,
a combination therapy of pegylated interferon a (PEG-
IFN-a) and guanosine analog ribavirin, has limited effi-
ciency, significant expense, poor tolerability and assure
long term eradication of the virus in less than half pro-
portion of treated patients largely dependent on the sig-
nificant variation among different HCV genotypes [5].
In Pakistan, about 75% of patients have no therapeutic
benefit to current therapy and approximately 20% of
patients have to discontinue therapy due to adverse side
effects [6,7]. In Pakistan the major HCV genotype is 3a
followed by 3b and 1a with a strong correlation between
chronic HCV infection and HCC with genotype 3a [8,9].
Due to the limitations of current therapy the develop-
ment of better tolerated therapeutic option for HCV is a
major objective of the present era. Currently research is
focused on exploiting new viral drug targets such as
sequence-specific and endogenous mechanism of gene
silencing like RNA interference (RNAi) for human ther-
apy and gene function studies.
RNAi, a recently described phenomenon in which
post-transcriptional regulation of protein expression, is
done by small double stranded RNA (dsRNA), called as
siRNA, inducing sequence-specific degradation of homo-
logous target mRNA recognized by antisense strand of
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peutic agent against HCV, because HCV replication takes
place in cytoplasm of liver cells, primary target, without
integration into host genome. Moreover, its genome
functions both as mRNA and a replication template. So
the destruction of HCV RNA could eliminate not only
protein synthesis but also viral replication. siRNA direc-
ted against the viral genes including 5’untranslated region
(5’UTR) of HCV 1a, 1b and 3a genotype (recently by our
group) effectively blocked the replication of viral repli-
cons in Huh-7 derived cell lines [17-30]. The develop-
ment of siRNA targeted to 5’UTR of local genotype 3a
which are crucial for initiation of viral translation pro-
vides better options for developing a rational antiviral
strategy against this local HCV genotype.
HCV is a positive single-stranded RNA (ssRNA) envel-
oped virus approximately 9.6 kb in length with an open
reading frame (ORF) encoding a large viral polyprotein
of about 3010 amino acids [31,32]. Viral translation is
mediated through an internal ribosome entry site (IRES)
found within the 5’UTR. The sequence of 5’UTR ~341 bp
in length is highly conserved even between different HCV
isolates. 5’UTR does not encode for functional protein and
contains IRES that initiate translation of the viral polypro-
tein in a cap-independent manner. The IRES has a key
role in translational events as it binds independently to the
40S ribosomal subunit and directs the ribosome to the
initiation codon of the HCV mRNA in order to facilitate
translation in a cap-independent manner [33,34]. It con-
tains four highly structured stem-lopped domains (domain
I-IV) that facilitate the translation of HCV RNA [35,36].
Domain I is not required for IRES activity but essential for
HCV replication, IRES in Domain II-IV mediates the cap
independent translation of viral genes [35,37,38]. Domain
III contains subdomains which are essential for the bind-
ing of 40S ribosomal subunit [39].
Viral escape and off-target effects due to RNA silencing
is a major problem in development of effective RNAi
based antiviral therapy but that can be overcome by find-
ing highly effective target sites. Huh-7 cells are highly
permissive for HCV replication and are widely used for
the study of HCV-associated diseases and antiviral strate-
gies like RNAi. The present study was undertaken to
study the effect of HCV genotype 3a 5’UTR specific siR-
NAs using a tagged mammalian expression vectors of
HCV 5’UTR-GFP and potential of these siRNAs in
reduction of viral titer in serum-infected Huh-7 cells.
Materials and methods
Source of samples
The local HCV-3a patient’s serum samples used in this
study were obtained from the CAMB (Center for
Applied Molecular Biology) diagnostic laboratory,
Lahore, Pakistan after quantification and genotype
assessment. Serum samples were stored at -80°C prior
to RNA extraction for cloning and viral inoculation
experiments. Patient’s written consent and approval for
this study was obtained from institutional ethics
committee.
Plasmid construction and siRNA designing
For the construction of expression plasmid, viral RNA
was isolated from 100 μl serum aliquots using Gentra
RNA isolation kit (Gentra System Pennsylvania, USA)
according to the manufacturer’s instructions. 100-200
ng extracted viral RNA was used for RT-PCR using the
SuperScript III one step RT-PCR system (Invitrogen Life
technologies, USA). HCV complementary DNA (cDNA)
of full length 5’UTR was amplified using specific pri-
mers; 5’UTR-F 5’GCAAGCTTACCTGCCTCTTAC-
GAGGC’3a n d5 ’UTR-R 5’AAGATATCGTTGCAC
GGTCTACG’3. After amplification, PCR product was
tagged with GFP gene, as 5’UTR contain IRES and does
not encode any protein, isolated from pUbC-GFP vector.
The ligated gene product was digested along with
pCR3.1 vector (kindly provided by Dr. Zafar Nawaz,
University of Miami, USA) employing primers with
EcoRV and XbaI restriction sites.
To express RNAi mechanism against 5’UTR region of
HCV-3a genome, siRNA oligonucleotides were designed
using the Ambion’ss i R N Ad e s i g nt o o lh t t p : / / w w w .
ambion.com/techlib/misc/siRNA_finder.html. The
designed siRNAs (HCV-3a 5’UTR and control scrambled
siRNA) were synthesized using Silencer siRNA construc-
tion kit according to the manufacturer’s instruction
(Ambion, USA). Negative control siRNA (scrambled
siRNA) with the same nucleotide composition as the
experimental siRNA but lacks significant sequence
homology to the HCV and human genome was design
(Table 1).
Cell culture and transfection
Huh-7 cell line was kindly provided by Dr. Zafar Nawaz
(University of Miami, USA) and routinely maintained in
Dulbecco’s modified eagle medium (DMEM) supplemented
Table 1 Sequence of siRNA oligonucleotides directed
against 5’UTR of HCV 3a genotype
No. siRNA name Sequences 5’-3’
1 Usi170- antisense AATCGCTGGGGTGACCGGGTCCCTGTCTC
2 Usi170-sense AAGACCCGGTCACCCCAGCGACCTGTCTC
3 Usi212- antisense AATACCCAGAAATTTGGGCGTCCTGTCTC
4 Usi212- sense AAACGCCCAAATTTCTGGGTACCTGTCTC
5 Usi272- antisense AAAGGCCTTGTGGTACTGCCTCCTGTCTC
6 Usi272- sense AAAGGCAGTACCACAAGGCCTCCTGTCTC
7 Sc-antisense AACCTGCATACGCGACTCGACCCTGTCTC
8 Sc-sense AAGTCGAGTCGCGTATGCAGGCCTGTCTC
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b o v i n es e r u m( S i g m aA l d r i c h ,U S A )a t3 7 ° Cw i t h5 %
CO2. To examine the effects of HCV-3a 5’UTR siRNAs,
Huh-7 cells were transfected with specific or scrambled
siRNAs along with HCV-3a 5’UTR-GFP vector. Briefly,
cells were seeded in 24-well (1 × 10
5/well) or 6-well (5 ×
10
5/well) plates and cultured in complete medium until
they became 60-80% confluent. Cells in 24-well plates
were transiently transfected with 10, 20, 40 nM/well of
specific siRNAs or scrambled siRNA along with 0.4 μgo f
HCV-3a constructed vectors in serum free media using
Lipofectamine™ 2000 (Invitrogen Life technologies, CA)
according to the manufacturer’s protocol. After 6 hrs
incubation at 37°C in 5% CO2, complete medium was
added to the cells. Protein analysis was carried out for
above mentioned experiments in 6-well plates with
100 μM/well of each siRNA. Cells were harvested at 24
and 48 hrs post-transfection for gene expression analysis.
Isolation of total RNA and gene expression
Total RNA from transfected and non-transfected cells
was isolated using TRIzol reagent (Invitrogen life tech-
nologies, CA) 24 hrs and 48 hrs post-transfection. To
analyze the effect of siRNA, cDNA was synthesized with
1 μg of total isolated RNA, using Superscript III cDNA
synthesis kit (Invitrogen life technologies, CA) and
semi-quantitative RT-PCR was done using primers of
5’UTR and GAPDH as control. Quantitative Real Time
PCR was carried out using Real Time ABI 7500 system
(Applied Biosystems Inc, USA) with SYBR Green mix
(Fermentas International Inc, Canada) using gene speci-
fic primers 5’UTR-F 5’TCACTCCCCTGTGAGGA-
ACT’3, 5’UTR-R 5’TCCCGGGGCACTCGCAAGCA’3.
GAPDH gene was used for normalization as control
using GAPDH-F 5’ACCACAGTCCATGCCATCAC’3
and GAPDH-R 5’TCCACCACCCTGTTGCTGTA’3.
The relative gene expression analysis was carried out by
the SDS 3.1 software (Applied Biosystems Inc, USA).
Each individual experiment was performed in triplicate.
Western Blotting
To determine the protein expression levels of GFP gene
under the control of 5’UTR, the transfected and non-
transfected (with and without siRNAs) cells were lysed
with ProteoJET mammalian cell lysis reagent (Fermentas,
Canada). Equal amounts of total proteins were subjected
to electrophoresis on 12% SDS-PAGE and electrophoreti-
cally transferred to a nitrocellulose membrane following
the manufacturer’s protocol (Bio-Rad, CA). After block-
ing non-specific binding sites with 5% skimmed milk,
blots were incubated with primary monoclonal antibodies
specific to GFP, Core, E1, E2 and GAPDH (Santa Cruz
Biotechnology Inc, USA) and secondary Horseradish per-
oxidase-conjugated anti-goat anti-mouse antibody
(Sigma Aldrich, USA). The protein expressions were
evaluated using chemiluminescence’s detection kit
(Sigma Aldrich, USA).
Viral inoculation and co-transfection with siRNA
Huh-7 cell line was used to establish the in vitro replica-
tion of HCV. A similar protocol was used for viral
inoculation as described previously [28,40]. Briefly, high
viral titer > 1 × 10
8 IU/ml from HCV-3a patient’ss e r a
was used as principle inoculum in these experiments.
Huh-7 cells were maintained in 6-well culture plates to
semi-confluence, washed twice with serum-free medium,
and then inoculated with 5 × 10
7IU/well viral load of
HCV-3a sera and 500 μl serum free media. Cells were
maintained overnight at 37°C in 5% CO2. Next day,
adherent cells were washed three times with 1× PBS,
complete medium was added and incubation was con-
tinued for 48 hrs. Cells harvested and were assessed for
viral RNA quantitatively by Real Time PCR. To analyze
the effect of siRNA on HCV infection, serum infected
Huh-7 cells were again seeded after three days of infec-
tion in 24-well plates and grown to 80% confluence with
2 ml medium. The cells were transfected with or with-
out 40 μM/well of siRNAs using Lipofectamine™ 2000
(Invitrogen Life technologies, CA) according to the
manufacturer’s protocol.
Viral Load
Cells were harvested for intracellular viral RNA determi-
nation using Gentra RNA isolation kit (Gentra System
Pennsylvania, USA) according to the manufacturer’s
instructions. For viral quantification (assay based on the
detection of 5’UTR) of viral copies) Sacace HCV quanti-
tative analysis kit (Sacace Biotechnologies Caserta, Italy)
was used. Briefly, 10 μl of extracted viral RNA was
mixed with an internal control derived from 5’UTR pro-
vided by Sacace HCV Real TM Quant kit and subjected
to viral quantification using Real Time PCR SmartCycler
II system (Cepheid Sunnyvale, USA). For viral protein
expression analysis at day 3 of viral inoculation, cells
were washed 3 times before harvesting and Western
blotting was performed.
Statistical Analysis
All statistical analysis was done using SPSS software
(version 16.0, SPSS Inc). Data are presented as mean ±
SD. Numerical data were analyzed using student’st - t e s t
and ANOVA. P value < 0.05 was considered statistically
significant.
Results
Screening of siRNAs against HCV 5’UTR at RNA level
Due to highly conserved region of HCV is indispensible
for both RNA translation and replication 5’UTR has
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sent study we designed and tested siRNAs targeting
5’UTR of HCV-3a to evaluate their antiviral activity
against important domains for translation initiation. To
test the HCV 3a directed siRNAs for their ability to sup-
press the well conserved HCV IRES (5’UTR) mediated
translation, three siRNAs were designed to trigger RNAi
and co-transfected with constructed vector into Huh-7
cells in different concentrations. Huh-7 cells were trans-
fected with pCR3.1/GFP/5’UTR, that expresses GFP
under the control of HCV 5’UTR, with and without
5’UTR specific siRNAs. All siRNAs inhibited the expres-
sion of GFP gene in a dose dependent manner (10, 20
and 40 nM) compared with control siRNA. The inhibi-
tory effect of Usi170 siRNA against 5’UTR is stronger at
24 hrs and 48 hrs post transfection even at low concen-
tration, while Usi212 and Usi272 shows more effect
after 24 and 48 hrs transfection at 40 nM compared
with scramble siRNA which showed no significant
change in expression of transfected vector to control
cells. In all the siRNA screening experiments, treatment
with synthetic and control siRNA did not affect the
levels of cellular gene GAPDH expression (Figure 1A).
The results of relative quantitative analysis revealed that
the transcript levels of the HCV 5’UTR were decreased
to 67% in treated cells with Usi170, 71% with Usi212
and 62% with Usi272 at 24 hrs post-transfection, while
65% with Usi170, 48% with Usi212 and 36.7% with
Usi272 at 48 hrs post-transfection. A maximum inhibi-
tion of 60-70% was observed with Usi170. GAPDH tran-
script levels showed no change in non-transfected or
transfected cells (Figure 1B).
At 24 and 48 hrs post-transfection, GFP expression in
Huh-7 cells was also photographed under a fluorescent
microscope; the results suggested that GFP fluorescence
was decreased in siRNA transfected cells as compared to
pUbC-GFP as a control vector, +ve control without
siRNA and scrambled siRNAs transfected cells. To deter-
mine whether changes in GFP fluorescence accurately
reflect underlying changes in GFP mRNA presence as a
result of RNAi triggered siRNAs, the protein extracts
derived from the siRNA transfected cells were tested for
the expression of GAPDH and found to be similar in all
Huh-7 cells, non-transfected and transfected with HCV
plasmid. Interestingly, western blotting showed that GFP
protein expression was efficiently inhibited by 65% in
cells co-transfected with pCR3.1/GFP/5’UTR, and siR-
NAs targeting 5’UTR, but not in the cells co-transfected
with positive vector and scramble siRNA after 24 and
48 hrs transfection. Moreover, Usi212 was found to be
more effective than Usi170 and Usi272 (Figure 2). This
data suggest that siRNA not only has a negative effect on
HCV-RNA but also it could decrease protein production
under the control of 5’UTR.
Effect of siRNAs against HCV virus in serum infected Huh-
7 cells
The present study was undertaken to design and test
siRNA as an alternative therapy against HCV, the results
against constructed vector indicate that siRNA targeting
HCV 5’UTR has the ability to inhibit the replication of
HCV RNA and protein in Huh-7 cells. Taken advantage
of the newly developed cell culture system of HCV
infection in liver cells [27,28,41], the effect of siRNAs
against whole virus was evaluated by treating cells with
siRNA. Huh-7 serum infected cells were treated with
5’UTR siRNAs and subsequently incubated for 3 days.
Total cellular RNA was extracted from Huh-7 cells and
Real Time PCR was performed with 5’UTR specific pri-
mers to analyze the down regulation of HCV RNA by
gene specific siRNAs. Maximal inhibition of HCV tran-
script levels was detected on Day 3 post transfection,
the results show an approximate 70-80% decrease in
HCV RNA levels in HCV serum infected Huh-7 cells
that were incubated with different gene specific-siRNAs.
This result was in accordance with Zekri et al., [27]
result who also showed that best inhibitory effect of siR-
NAs against 5’UTR on 3
rd day of post transfection. No
significant inhibition was detected in cells transfected
with the negative control siRNA. siRNAs targeting IRES
containing 5’UTR showed upto 80% inhibition of viral
load. Taken together a significant level of HCV genotype
3a viral RNA suppression by siRNA against 5’UTR was
o b s e r v e da n dt h e s ed a t as u g g e s tan e g a t i v ei m p a c to f
gene-specific siRNAs on HCV replication (Figure 3A).
Moreover, siRNAs effect on HCV proteins (Core, E1,
and E2) in serum infected Huh-7 cells was detected
using gene specific antibodies. Densitometric analysis
revealed no significant inhibition at protein levels in
cells transfected with the negative control siRNA
(scrambled siRNA). Two siRNAs targeting IRES con-
taining 5’UTR (Usi170 and Usi272) showed upto 60-70%
inhibition of viral proteins expression especially E2 and
upto 40% inhibition of Core protein expression (Figure 3B).
Together, the data suggest a negative impact of chemically
synthesized siRNA against 5’UTR on the down regulation
of HCV genes activity as a target for preventing HCV
induced HCC development. These results are in accor-
dance with our previous data in which Core and envelope
genes were targeted by siRNAs which had a inhibitory
effect on total viral titre [28].
Discussion
As a gene silencing mechanism, RNAi represents an excit-
ing technology with potential applications for treatment of
viral diseases such as HCV. Several laboratories have
demonstrated that RNAi efficiently inhibits viral replica-
tion and expression of HCV genotype 1a and 1b using
replicon cell lines by targeted 5’UTR, Core, E2, NS3, NS4b
Khaliq et al. Virology Journal 2011, 8:221
http://www.virologyj.com/content/8/1/221
Page 4 of 9and NS5b sequences by using RNAi [42]. Recently our
group tested siRNAs against structural genes of HCV gen-
otype 3a which is the most prevalent in Pakistan, showing
upto 80% inhibition at RNA and protein levels [28]. A
potential problem that may arise in RNAi based approach
is the error prone nature of HCV genome but this pro-
blem can be overcome by designing siRNAs against highly
conserved region like HCV 5’UTR. The IRES containing
5’UTR is the most highly conserved region of HCV gen-
ome with more than 90% identity between the sequences
of distantly related strains [23,43]. It was proposed that
RNAi-based antiviral strategy could be used to degrade
5’UTR of HCV 3a genotype. Given this scenario in the
present study, RNAi was utilized to determine the efficacy
of this technique for inhibition of HCV 3a 5’UTR as an
alternative therapeutic option.
Figure 1 HCV 3a 5’UTR specific siRNAs inhibit mRNA expression. A) Huh-7 cells were transfected with 0.4 μg of constructed HCV vector
or mock-treated along with or without 10 nM, 20 nM and 40 nM of siRNAs for 24 and 48 hrs. Cells were harvested and relative RNA
determinations were carried out using semi-quantitative PCR. Gene expression results from semi-quantitative PCR are given for increasing
concentrations of Usi170, Usi212 and Usi272 siRNAs against HCV 3a 5’UTR. Expression levels for mock-transfected (M), HCV 3a 5’UTR expression
plasmid (U), scramble siRNA (Sc), 100 bp DNA Ladder (L) and GAPDH are also shown. B) Huh-7 cells were transfected pCR3.1/GFP/5’UTR vector
or mock-treated along with or without 40 nM of siRNAs for 24 and 48 hrs. Total cellular RNA extracted, after 24 and 48 hrs post transfection, was
quantified by Real Time PCR using gene specific primers in comparison to Mock. Gene expression results from Real Time PCR shows that Usi170
and Usi272 siRNAs against HCV 3a 5’UTR decrease RNA expression both after 24 and 48 hrs post transfection. GAPDH was used as internal
control. Three independent experiments were performed having triplicate samples. Error bars indicate mean S.D, p < 0.01.
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HCV translation which displays greatest homology
between different genotypes and has been targeted in
many studies with different approaches. 5’UTR have
been found effective targets, with inhibition of IRES-
dependent translation in replicon systems reaching
almost 80% in some cases against HCV 1a and 1b geno-
types [19,23,26,30], suggesting a considerable potential
of this approach with respect to HCV inactivation. Korf
et al., [44] reported siRNAs against domain II and III of
5’UTR substantially inhibited subgenomic HCV replica-
tion driven by HCV IRES. In the present study, all siR-
NAs designed targeting 5’UTR were located in the
Domain III which is thought to be important in 40S
ribosomal subunit binding and initiation of translation.
It has been reported that Core protein binds to viral
genomic RNA via interaction with Domain III of 5’UTR
during viral replication [45,46]. By considering these
facts, we designed and tested siRNA against these
regions. Huh-7 cells are most suitable for virus replica-
tion and other studies; Chemically synthesized siRNAs
can be introduced into cells when formulated with lipo-
philic reagents [47-50], we used Huh-7 cells to study
siRNA effect. siRNAs against 5’UTR of HCV 3a with the
GFP gene as a reporter reduced the RNA of 5’UTR and
GFP in a dose dependent manner upto 75% to 80% with
Figure 2 HCV-3a 5’UTR-specific siRNA inhibit GFP protein expression. A) Silencing effect of HCV-3a 5’UTR- siRNA on 5’UTR-GFP tagged
protein. GFP fluorescence was observed under illumination with 360-400 nm light that excites GFP fluorescence (20× magnification) with and
without siRNA tranfected Huh-7 cells. B) Silencing of HCV-3a 5’UTR-GFP gene by siRNAs using GFP specific antibodies show reduction at protein
expression level. The protein expression levels were determined by Western blot analysis after 24 and 48 hrs transfection with mock (M), HCV 3a
5’UTR expression plasmid (U), with and without HCV 3a siRNAs (Usi170, Usi212 and Usi272) and scramble siRNA (Sc) in Huh-7 cells. Protein levels
for GAPDH gene are also shown as internal control.
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(Figure 1). The effect of gene silencing was evident even
after 24 hrs post siRNA transfection in our study and
therefore, demonstrating the ability of in vitro synthe-
sized siRNAs against silencing the target gene expression.
Guha et al. [51] reported that in vitro cell culture
models can at best demonstrate the infectivity of the
virus and used in evaluating drugs for antiviral activity
or inhibition of HCV infection. Most of the studies all
over the world are conducted in Huh-7 derived cell
lines and with replicons supporting HCV RNA transcrip-
tion and protein synthesis. Recently different groups have
studied the HCV replication in serum infected liver cell
lines for the study of different HCV genotypes which
mimics the naturally occurring HCV virions biology and
kinetics of HCV infection in humans [28,52-54]. We
infected Huh-7 cells with native viral particles from HCV
3a positive serum, the most prevalent type in Pakistan
Figure 3 Silencing effect of HCV 3a genes-specific siRNAs in Huh-7 cells infected with HCV 3a sera. After 24 hrs post plating, Huh-7 cells
were transfected with siRNAs against HCV-3a genes alone and incubated. Next day, cells were washed 5 times with 1XPBS and incubation was
continued for additional 48 hrs. Cells were harvested and HCV RNA levels were quantified by Real Time PCR. A) Effect of 5’UTR specific siRNAs
against HCV. B) On 3
rd day of infection cells were harvested and protein was subjected to SDS PAGE and expression levels were determined by
Western blot analysis. In the figure Normal serum infected cells (Nser), HCV-3a serum infected cells (Ser3a), Cells infected with scrambled siRNA
(Sc), Gene specific-siRNA against 5’UTR. Data are expressed as mean percent viral load of non-siRNA treated samples. Three independent
experiments with triplicate determinations were performed. Error bars indicate, mean S.D p < 0.05 verses S3a.
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NAs against 5’UTR in the present study were further
screened against HCV in serum infected Huh-7 cells. An
exciting finding of this study is decline of HCV viral titer
to a maximum of 80% with gene specific siRNAs followed
by reduction in HCV protein expression. HCV replication
in the Huh-7 cells was observed through detection of
5’UTR of viral copies by Real Time PCR in cells from 3
rd
day post infection. Bian et al. [55] reported that 14 amino
acids from the C-terminus of Core gene are required for
proper function of E1 and at least 12 amino acids from C-
terminus of E1 genes are required for E2 function, influen-
cing the proper glycosylation of E1 and E2 gene. The siR-
NAs in the present study which showed reduction in viral
titer were also tested for effect on HCV proteins expres-
sion as they are translated in a form of single polypeptide
and found to be equally effective in HCV protein expres-
sion, while the effect was much greater against E2 protein
expression by all siRNAs (Figure 3). This effect may be as
a result of 5’UTR mediated translation inhibition and also
due to the inability of interaction between 5’UTR domain
III and Core during virion assembly. Our data is in agree-
ment with Zekri et al.[ 2 7 ] ,w h od e m o n s t r a t e dt h a ts i R -
NAs against 5’UTR of HCV genotype-4 inhibited HCV
replication in serum infected Huh-7 cells and Khaliq et al.
[28] who tested siRNAs against HCV 3a in serum infected
cells and observed the down regulation of HCV RNA.
Treatment of siRNAs revealed significant inhibitory effect
on HCV copy number indicating the potential of siRNAs
as an efficient therapeutic strategy.
Our results demonstrate that siRNA targeting HCV
5’UTR can elicit viral RNA from infected cell and poten-
tially offer an efficient therapeutic option for HCV infec-
tion. These results are in agreement with the previous
studies which suggested that siRNA is the most efficient
nucleic acid based antiviral approach that can be utilized
to degrade HCV genome in the infected cells. Moreover,
based on these results it is suggested that RNAi-mediated
silencing of the local HCV-3a 5’UTR may be one of the
important therapeutic opportunities against HCV-3a gen-
otype. Recently Pan et al. [56] reported that RNAi (against
5’UTR) can be applied in combination with IFNa without
effecting signal transduction to hepatocytes or interfering
using RNAi which significantly enhanced their individual
antiviral effects. Therefore, it can also be speculated from
our pilot study that therapeutic induction of RNAi against
HCV-3a 5’UTR either alone or in combination with IFN
treatment might represent an alternative approach for
future treatment of chronic infection.
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